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Available online 9 June 2012Antibody-based drugs such as infliximab (IFX) are effective for the treatment of inflammatory
bowel disease (IBD) and other immune-mediated disorders. The development of antibodies
against these drugs may result in unfavorable consequences, including the loss of drug efficacy,
hypersensitivity reactions, and other adverse events. Therefore, accurate monitoring of serum
drug and anti-drug antibody levels should be an important part of therapy for patients being
treatedwith an antibody-based drug. Currentmethods for the assessment of anti-drug antibodies
and drug levels, involving various bridging ELISA and radioimmunoassay techniques, are limited
by their sensitivity, interference, and/or complexity. To overcome these limitations, we have
developed a non-radiolabeled homogeneous mobility shift assay (HMSA) to measure the
antibodies-to-infliximab (ATI) and IFX levels in serum samples. Full method validation was
performed on both the ATI- and IFX-HMSA, and the clinical sample test results were also
compared with those obtained from a bridging ELISA method to evaluate the difference in
performance between the two assays. Validation of the ATI-HMSA revealed a lower limit of
quantitation of 0.012 μg/mL in serum. The linear range of quantitationwas 0.029–0.54 μg/mL. The
intra- and inter-assay precisionwas less than 20% of coefficient of variation (CV), and the accuracy
(% error) of the assay was less than 20%. In serum samples, ATI as low as 0.036 μg/mL can be
measured, even in the presence of 60 μg/mL of IFX in the serum. Sera from 100 healthy subjects
were tested to determine the cut point of the assay. ATI-positive samples that had been previously
analyzed by using a bridging ELISA from 100 patients were also measured by the new method.
Therewas a high correlation between the twomethods for ATI levels (pb0.001). Significantly, the
new method identified five false-positive samples from the bridging ELISA method. Validation of
the mobility shift IFX assay also showed high assay sensitivity, precision and accuracy. The HMSA
method may also be applied to other protein-based drugs to accurately detect serum drug and
anti-drug antibody levels.
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Tumor necrosis factor-alpha (TNF-α) plays a pivotal role
in the pathogenesis of inflammatory bowel disease (IBD),
rheumatoid arthritis (RA), and other autoimmune disorders
(Suryaprasad and Prindiville, 2003; Kopylov et al., 2011;
Sandborn et al., 2010). Protein-based drugs that block TNF-α
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IgG1κ) or adalimumab (a fully human monoclonal antibody)
are effective in reducing disease activity of these inflamma-
tory disorders (Tracey et al., 2008). However, over 30% of
patients fail to respond to anti-TNF-α therapy, and many
who initially respond later require higher or more frequent
dosing due to a failure to maintain the initial response,
especially in the IBD patient population (Hanauer et al., 2002;
Gisbert and Panes, 2009; Regueiro et al., 2007). There is now
compelling evidence that demonstrates that the loss of
response in these patients is a result of a failure to achieve
and maintain adequate therapeutic drug levels in blood and/
or from the formation of anti-drug antibodies (Miheller et al.,
2012). Anti-drug antibodies could cause adverse events such
as serum sickness and hypersensitivity reactions (Brennan et
al., 2010; Emi et al., 2010), and it is hypothesized that their
formation may also increase drug clearance and/or neutralize
the drug effect, thereby potentially contributing to the loss of
response. Moreover, recent data suggest that the standard
dosing regimen for TNF-α-blocking drugs may be suboptimal
in some IBD patients, and an individualized dosing regimen
to achieve therapeutic drug levels may be important to
maximize the initial drug response and to maintain remission
(Colombel et al., 2012). Therefore, accurate monitoring of
serum drug and anti-drug antibody levels should be an
important part of therapy for patients being treated with
protein-based drugs. While monitoring for serum drug levels
and for the formation of anti-drug antibodies are routine
components of early drug development and are mandatory
during clinical trials (Shankar et al., 2006), these activities
have generally not been adopted in clinical practice. This
deficiency may be partially explained by technical issues of
the available monitoring assays, which limit their utility as
part of routine clinical practice.
Current methods for the assessment of anti-drug anti-
bodies and drug levels in serum mainly utilize the bridging
ELISA method (Baert et al., 2003) and, occasionally, the
radioimmunoassay (RIA) method (Aarden et al., 2008).
However, a major limitation of the bridging ELISA methods
in measuring anti-drug antibody levels is the inability to
accurately detect the antibodies in the presence of the drug in
circulation due to cross-interference. Specifically, the circu-
lating drug interferes with the capture of anti-drug anti-
bodies by the same drug initially coated on the ELISA plate,
thus limiting the ELISA's ability to detect anti-drug anti-
bodies, resulting in a lower sensitivity for detection in the
presence of IFX. Therefore, ELISA methods can only measure
anti-drug antibodies accurately when there is no drug in
circulation, which significantly limits its clinical utility. The
disadvantages of the RIA method are associated with the
complexity and safety concerns related to the handling of
radioactive material as well as the prolonged incubation time
needed to reach equilibrium for proper measurements.
Therefore, there is a large unmet medical need to develop a
simple and accurate assay that can overcome these limita-
tions and provide clinicians with valuable quantitative
measurements that they can then use to optimize the
management of patients on biologic therapies. Here, we
have developed and validated a novel homogenous mobility
shift assay (HMSA) using size-exclusion high-performance
liquid chromatography (SE-HPLC) to quantitatively measureboth induced antibodies-to-infliximab (ATI) levels and IFX
levels in serum samples collected from IBD patients being
treated with IFX.
2. Materials and methods
2.1. Materials
Individual serum samples from healthy controls were
obtained from blood bank donors (Golden West Biologics,
Temecula, CA). Sera from IBD patients treated with IFX were
obtained from residual samples leftover after testing for ATI
and IFX levels in our laboratories and the patient information
was de-identified. Unless otherwise noted, all reagents and
chemicals were obtained from either Thermo Fisher Scientific
(Waltham, MA) or Sigma Aldrich Corporation (St. Louis, MO).
2.2. Conjugation of IFX and TNF-α
Commercially-available infliximab (RemicadeTM, Janssen
Biotech, Inc., Horsham, PA) was buffer exchanged with phos-
phate buffered saline (PBS, pH 7.3) and labeled with AlexaFluor
488 (Life Technology, Carlsbad, CA) following the manufac-
turer's instructions. Briefly, a reaction mixture consisting of
10 mg of IFX, 154 μg of AlexaFluor 488 dye, and 1 mL 1× PBS
(pH8.0)was incubated in the dark at room temperature (RT) for
1 h with constant stirring. A desalting column was then used to
remove free AlexaFluor 488, and the infliximab-AlexaFluor 488
conjugate (IFX-488) was collected. The protein concentration
and labeling efficiency of the conjugate was measured using a
NanoDrop Spectrophotometer (Thermo Fisher Scientific,
Waltham, MA). The NanoDrop spectrophotometer measures
the A280 value for the protein concentration and the A494 value
for AlexaFluor 488 concentration. The approximate molar
extinction coefficient of the AlexFluor 488 dye at 494 nm is
71,000 cm−1 M−1 and the labeling efficiency is calculated as
follows:
moles dye per mole protein
¼ A494  dilution f actor
71;000 protein concentration Mð Þ
Only those conjugates containing 2 to 3 fluorescent dyes
per antibody qualified for the ATI-HMSA.
The procedure for the labeling of recombinant TNF-α
(RayBiotech, Inc, Norcross, GA) with AlexaFluor 488 was
identical to that used for the labeling of IFX. The molar ratio
of TNF-α to fluorescent dye in the reaction mixture was 1:6
and the resulting TNF-α-AlexaFluor 488 conjugate (TNF-488)
contained 1–2 dye molecules per TNF-α.
2.3. Internal control (IC) for the HPLC analysis and preparation
of IFX-488/IC and TNF-488/IC
Activated AlexaFluor 488 (1 mg) and 4 mL 1 M Tris buffer
(pH 8.0) were mixed for 1 h on a magnetic stirrer at RT to
block the active site on the dye. The resulting solution was
buffer-exchanged with 1× PBS. The blocked AlexaFluor 488
was used as the IC and combined with either IFX-488 or TNF-
488 at a molar ratio of 1:1. The resultant IFX-488/IC and TNF-
488/IC were used to normalize the labeled IFX and TNF-α in
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IFX-488/IC and TNF-488/IC employed for the HPLC analysis
was based on the IFX-488 and TNF-488 concentrations only.
2.4. Preparation of calibration standards, quality control samples
and procedure for the ATI bridging ELISA
ATI-positive sera were prepared by pooling individual
patient serum samples identified as containing high concen-
trations of ATI and negative for IFX as determined by ELISA
method (Baert et al., 2003). In brief, the ATI bridging ELISA is
a microplate based, double antigen formatted assay where
IFX is coated on the solid phase 96-well plate to capture the
ATI from the patient serum samples. The captured ATI is
detected through binding to a biotinylated IFX. The amount
of bound biotin on the microplate is determined with the
addition of a neutravidin-HRP conjugate which transforms
the substrate O-phenylenediamine to a chromogenic product
that is measured in a microplate reader at 490 nm. In the
bridging ELISA, an affinity purified polyclonal rabbit anti-
mouse IgG F(ab')2 (Thermo Fisher Scientific, Waltham, MA)
is used to generate the standard curve for calculation of the
relative amount of ATI in the patient serum sample. In HMSA,
the relative amount of ATI in the pooled serumwas estimated
by comparing the fluorescent intensity of the ATI-IFX488
immune complex in SE-HPLC with a known concentration of
IFX-488. The pooled ATI calibration serum was aliquoted and
stored at−70 °C. To generate a standard curve, one aliquot of
the stock ATI calibration serum was thawed and diluted to 2%
with normal human serum (NHS) in HPLC assay buffer (1×
PBS, pH 7.3) to concentrations of 0.006, 0.011, 0.023, 0.045,
0.090, 0.180, 0.360, and 0.720 μg/mL. Three quality control
(QC) samples were prepared by diluting the calibration
serum in assay buffer with 0.1% BSA to yield the high
(0.36 μg/mL), mid (0.18 μg/mL), and low (0.09 μg/mL) con-
trol concentrations. Similarly, IFX calibration standards were
prepared by serially diluting a stock solution of 93.75 μg/mL
in 100% NHS. After serial dilution, each standard was added
to the assay plate and diluted with assay buffer containing
0.1% BSA to yield concentrations of 0.03, 0.06, 0.12, 0.23, 0.47,
0.94, 1.88 and 3.75 μg/mL of IFX and final NHS concentration
of 4% in the reaction mixture. Three IFX QC samples were
prepared by diluting the IFX calibration standard with assay
buffer and 0.1% BSA to yield the high (0.63 μg/mL), mid
(0.31 μg/mL) and low (0.16 μg/mL) control concentrations.
2.5. Assay procedures
2.5.1. ATI homogenous mobility shift assay (ATI-HMSA)
The assay was prepared in a 96-well plate format. In order
to reduce interference from circulating drug, an acid dissocia-
tion step was employed. Briefly, a solution containing a 24 μL
aliquot of serum sample, 5.5 μL 0.5 M citric acid (pH 3.0), and
10.9 μL HPLC grade water were added to each well and
incubated for 1 h at RT to free the ATI in the patient serum
samples from other bound proteins. Following the acid
dissociation step, 6 μL of a 74 μg/mL IFX-488/IC solution was
added and the reaction mixture was immediately neutralized
with 27.6 μL of 10x PBS (pH 7.3). The plate was incubated for
another hour at RT on an orbital shaker to complete the
formation of the immune complexes. The incubated serumsamples were then diluted to a final serum concentration of 2%
by pipetting 18.4 μL of each sample solution, 22.6 μL 10× PBS
(pH 7.3), and 259 μL HPLC grade water into the wells of a new
96-well plate. In this plate, the first four wells contained,
respectively: 300 μL each of HPLC buffer as a blank, aqueous
SEC1 column standard (Phenomenex, Torrance, CA) tomonitor
the resolution of the HPLC column, acid-dissociated 2% NHS,
and acid-dissociated 2% NHS with 110 ng IFX-488/IC for
calibrating the HPLC system. The next eight wells contained
300 μL each of the ATI calibration standards (0.006, 0.011,
0.023, 0.045, 0.090, 0.180, 0.360, and 0.720 μg/mL)with 110 ng
IFX-488/IC for generating the standard curve. The next nine
wells contained, respectively, 300 μL each of the three QC
controls (high, mid and low) in triplicate with 110 ng IFX-488/IC
to establish the precision and accuracy of the assay. The
remaining wells were then filled with 300 μL of the prepared
patient serum samples. After mixing on an orbital shaker for
1 min at RT, the samples were filtered through a MultiScreen-
Mesh Filter plate equipped with a Durapore membrane
(0.22 μm; EMD Millipore, Billerica, MA) into a 96-well receiver
plate (Nunc, Thermo Fisher Scientific, Waltham, MA). The
recovered solutions in the receiver plate were then transferred
sequentially to the loading vials of an autosampler at 4 °C in an
Agilent Technologies 1200 series HPLC system (Santa Clara, CA).
A 100 μL aliquot from each vial was loaded onto a BioSep SEC-
3000 column (Phenomenex, Torrance, CA) and the column
effluent was monitored by a fluorescent detector at excitation
and emission wavelengths of 494 nm and 519 nm, respectively.
The chromatography was run at the flow-rate of 1 mL/min for a
total of 20 min with 1× PBS (pH 7.3) as the mobile phase.
ChemStation Software (Agilent Technologies, Santa Clara, CA)
was used to set up and collect data from the runs automatically
and continuously. The time needed to process all the calibration
standards, controls, and 35 patient serum samples was ~22 h for
a single HPLC system.
2.5.2. IFX homogeneous mobility shift assay (IFX-HMSA)
The procedure for the IFX-HMSA was similar to the ATI-
HMSA, except that the acid dissociation step was omitted in
the preparation of the patient serum samples. IFX spiked in
pooled NHS were used as calibration standards. The assays
were performed by incubating the TNF-488/IC with serum
samples or calibration standards to reach equilibrium. As in
the ATI-HMSA method, the reaction mixtures were then
filtered and analyzed by the SE-HPLC system.
2.6. Data analysis
Data analysis was performed with the use of a proprietary
automated program run on R software (R Development Core
Team, Vienna, Austria). Briefly, the R program opened the
ChemStation files collected in the entire run's analyses and
exported the raw spectra for an experiment of the user's
choosing. The program then normalized the spectra, deter-
mined the area under each peak, and calculated the proportion
of total peak areas shifted to the bound ATI/IFX-488 complexes
over the total bound and free IFX-488 peak areas in the ATI-
HMSA and in a similar manner for the IFX-HMSA. With these
calculated data, a standard curve was generated by fitting a
five-parameter logistic curve to the eight calibration samples
using a non-linear least squares algorithm. The residual sum of
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Using this curve function, the five optimized parameters, and
each sample's proportion of shifted area, concentrations for the
unknown samples and the control samples (high,mid and low)
were determined by interpolation. To obtain the actual ATI and
IFX concentration in the serum, the interpolated results from
the standard curve were multiplied by the dilution factor. In
addition, the ATI values determined in our clinical laboratory
are reported as ATI units/mL, where one ATI unit/mL is
equivalent to 0.18 μg ATI protein/mL.
2.7. ATI-HMSA and IFX-HMSA assay performance validation
2.7.1. Characterization of the standard curves
Performance characteristics of the ATI-HMSA calibration
standards in the concentration range of 0.006–0.720 μg/mL and
the three QC samples (high, mid, and low) were monitored
over 26 separate experiments, while the performance charac-
teristics of the IFX-HMSA calibration standards in the concen-
tration range of 0.03–3.75 μg/mL and the three QC samples
were monitored over 38 separate experiments. Standard curve
performance was evaluated by both the coefficient of variation
(CV) for each data point as well as the recovery percentage of
the high, mid, and low QC controls. Acceptance criteria were
defined as CV b20% for each QC sample.
2.7.2. Assay limits determination
The limit of blank (LOB) was determined by measuring
replicates of the standard curve blanks across multiple days.
The LOB was calculated using the equation: LOB=Mean+
1.645×SD (Armbruster and Pry, 2008). The limit of detection
(LOD) was determined by utilizing the measured LOB and
replicates of ATI or IFX‐positive controls that contained a
concentration of ATI or IFX that approached the LOB. The
LOD was calculated using the equation: LOD=LOB+
1.645×SD(low concentration sample) (Armbruster and Pry,
2008). The lower and upper limits of quantitation (LLOQ
and ULOQ, respectively) were the lowest and highest amounts
of an analyte in a sample that could be quantitatively
determined with suitable precision and accuracy. LLOQ and
ULOQ were determined by analyzing interpolated concentra-
tions of replicates of low concentration or high concentration
serum samples containing spiked in IFX or ATI. The LLOQ and
ULOQwere each defined as the concentration that resulted in a
CV b30% and standard error b25%.
2.7.3. Assay precision
Nine replicates of ATI- or IFX-positive controls (high, mid,
and low)were run during the same assay tomeasure intra-assay
precision and accuracy. The minimum acceptable CV range was
b20% and accuracy (% error) was b25%. Inter-assay precision
was determined by running the assay standard and controls by
the same analyst on different days and different instruments,
followed by three analysts performing the same assay on
different days with the same instrument. The minimum
acceptable criteria were b20% for CV and b25% for accuracy.
2.7.4. Linearity of dilution
Linearity of the ATI-HMSA and the IFX-HMSA was deter-
mined by performing a two-fold serial dilution of an ATI- or an
IFX-positive sample to graphically determine the relationshipbetween the observed and the expected concentrations. Both
the R2 value and the slope of each linear regression curve were
calculated to evaluate the linearity of the assays.
2.8. Cut point determination
Serum samples from drug-naïve healthy donors (n=100;
Golden West Biologics. Temecula, CA) were analyzed to
determine the screen cut point for the ATI-HMSA and IFX-
HMSA.We set the cut point to have an upper negative limit of
approximately 97.5%. It was calculated by using the mean
value of individual samples interpolated from the standard
curve plus 2.0 times the standard deviation (SD), where 2.0
was the 97.5th percentile of the normal distribution. Receiver
operating characteristic analysis was also used to estimate
the clinical specificity and sensitivity for the ATI-HMSA.
3. Results
3.1. HMSA principles
The principles of the ATI-HMSA and the IFX-HMSA are
illustrated in Fig. 1A and B, respectively. The ATI-HMSA in
Fig. 1A involved incubating an ATI-containing serum sample
with IFX-488/IC at RT for 1 h to form IFX-488/ATI immune
complexes. At the end of the incubation, the immune
complexes and the remaining free IFX-488 were separated by
SE-HPLC and the peak areas of the bound IFX-488 and the free
IFX-488 were quantified by fluorescence detection. A pooled
ATI-positive serumwas used as the calibration standard.When
serial dilutions of the ATI calibration standard were incubated
with IFX-488, dose-dependent immune complexes were
formed with concomitant reduction of the free IFX-488, all of
which could be resolved by SE-HPLC analysis, as shown in
Fig. 2A. Fig. 2B shows the standard curve generated by plotting
the data from Fig. 2A. The lowest concentration of ATI in the
standard curve was 0.006 μg/mL.
Fig. 1B illustrates the principle of the IFX-HMSA, which is
similar to that of the ATI-HMSA. Incubation of the fluores-
cently labeled TNF-α (TNF-488) with the anti-TNF antibody
IFX resulted in the formation of higher molecular weight
immune complexes (TNF-488/IFX). The immune complexes
and the remaining free TNF-488were separated and quantified
by SEC-HPLC. Purified IFX spiked in NHS at a concentration of
93.75 μg/mL was used as the IFX calibration standard. Using
similar methodology to the ATI-HMSA, the immune complexes
formed by combining the IFX calibration standards with TNF-
488 were separated from the remaining free TNF-488 (Fig. 3A)
and a standard curve was generated with the results (Fig. 3B).
3.2. Analytical validation of ATI- and IFX-HMSA
3.2.1. Validation of the standard curve and assay limits
To validate the standard curve, the performance character-
istics of the ATI calibration standards within the concentration
range of 0.006–0.720 μg/mL were monitored over 26 experi-
ments by multiple analysts using different instruments over
different days (Table 1). The mean RSS for the five-parameter
fitted curvewas b0.001 (n=26)whichwas significantly better
than our acceptability criterion of RSS=0.01 (Fig. 2B). The
error for the back-calculated values of the standards was
AB
Fig. 1. Schematic illustration of the principles of the (A) ATI-HMSA and (B) IFX-HMSA. In (A), fluorescently labeled IFX (IFX-488; MW ~150 kD) is incubated with
serum samples containing ATI (MW ~150–900 kD). The newly-formed immune complexes of ATI/IFX-488 have significantly higher MW than the free IFX-488,
and can be separated and quantified by SE-HPLC with fluorescent detection. (B) Similarly, fluorescently labeled TNF-α (TNF-488, MW ~51 kD) binds to IFX in
serum samples and the newly-formed immune complexes with increased MW of 51 kD to >200 kD can then be separated and quantified.
A
B
Fig. 2. Overlapping SE-HPLC chromatograms of (A) the ATI calibration
standards and (B) the ATI-HMSA-generated standard curve. (A) The greater
the amount of ATI calibration standard added to the IFX-488 reaction mixture,
the greater the shift of free IFX488 (10–11.5 min) towards the formation of
immune complexes (6.7–9.5 min); however there were no changes observed
for the internal control (14 min). (B) The standard curve was generated by
plotting the ratios of the proportion of the shifted area over total area vs. the
concentration of ATI in the reaction mixture. LU=luminescent units.
A
B
Fig. 3. Overlapping SE-HPLC chromatograms of (A) the IFX calibration
standards and (B) the IFX-HMSA-generated standard curve. (A) The greater
the amount of IFX calibration standard added to the TNF-488 reactionmixture,
the greater the shift of free TNF-488 (11.5–12.5 min) towards the formation of
immune complexes (6.7–9.5 min); however no changes were observed for the
internal control (14 min). (B) The IFX-HMSA standard curve was generated
using the same method as the ATI-HMSA. LU=luminescent units.
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Table 1
Characteristics of the ATI-HMSA standard curves.
Standard
(μg/mL)
Back calculated
concentration
(mean, μg/mL)
Error
(%)
CV (%) Normalized
ratio (mean)
SD CV
(%)
n
0.720 0.707 1.89 1.06 0.992 0.007 0.74 26
0.360 0.373 3.64 1.33 0.771 0.037 4.83 26
0.180 0.172 4.7 1.54 0.438 0.033 7.53 26
0.090 0.091 0.97 1.58 0.235 0.02 8.54 26
0.045 0.050 11.25 3.2 0.127 0.012 9.51 26
0.023 0.026 16.27 6.2 0.07 0.009 12.77 26
0.011 0.012 2.71 28.71 0.043 0.011 26.77 26
0.006 0.000 92.12 169.83 0.029 0.01 33.01 26
0.000 0.006 N/A N/A 0.011 0.003 22 60
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The CV was b10% for concentrations above 0.011 μg/mL and the
dynamic range of the assay was two orders of magnitude. To
establish the LOB, blank samples were tested (negative
control, 0 μg/mL) along with the standard curve. Themean
proportion value of the shifted area (immune complexes) over
the total area determined from the blanks was 0.011±0.003
(n=60). The LOB was thus calculated to be 0.015
(mean+1.645×SD) and the extrapolated ATI concentration
from the standard curve was 0.006 μg/mL (Table 1). To
determine the LOD, the extrapolated value of the lowest
standard concentration (0.006 μg/mL) was obtained as 0.014±
0.003 μg/mL (n=26). The LOD was calculated from the LOB
and the SD from the lowest concentration in the standard curve
with b30% error: LOD=LOB+1.645×SD(low concentration sample)
which was 0.012 μg/mL. The LLOQ for the ATI-HMSA assay was
0.011 μg/mL, which was determined by the interpolated con-
centrations of replicates of the low ATI concentration with CV
b30%. The ULOQ for the ATI-HMSA assay was 0.54 μg/mL, which
was similarly determined by the interpolated concentrations of
replicates of the high ATI concentration with CV b20%. The
effective serum concentrations corresponding to the LLOQ and
theULOQ for the ATI-HMSAwere determined bymultiplying the
concentration with the dilution factor (50), which corresponded
to 0.56 μg/mL and 27 μg/mL, respectively.
The performance characteristics of the IFX-HMSA standard
curve in the concentration range of 0.03–3.75 μg/mL were
similarly assessed over 38 experiments by multiple analysts
usingdifferent instruments ondifferent days (Table 2). The same
methodswere used to determine the LOB, LOD, LLOQ, and ULOQ
as described for the ATI-HMSA. The LOB, LOD, LLOQ, and ULOQ
for the IFX-HMSA were 0.0027, 0.0074, 0.039, and 1.36 μg/mL,Table 2
Characteristics of the IFX-HMSA standard curves.
Standard (μg/mL) Back calculated concentration
(mean,μg/mL)
Error (%) CV
3.75 2.375 36.658 11
1.88 2.222 18.528 10
0.94 0.925 1.305 7
0.47 0.455 2.928 1
0.23 0.247 5.396 3
0.12 0.131 11.509 3
0.06 0.060 1.617 12
0.03 0.014 53.745 54respectively. The effective IFX serum concentration for the LLOQ
and ULOQ were 0.98 and 34 μg/mL (dilution factor=25).
3.2.2. Assay precision and accuracy
To assess the precision and accuracy of the ATI-HMSA and
the IFX-HMSA, twomethodswere used. First, we used the high,
mid, and low QC samples in both assays to determine their
recovery rate. As shown in Table 3, the ATI-HMSA intra-assay
precision had a CV b4% and the accuracy rate was b12% error.
The intra-assay precision and accuracy for the IFX-HMSA were
b6% and b10% error, respectively (Table 4). Second, we tested
the high, mid, and low control samples over different runs and
instruments and bymultiple analysts. The inter-assay precision
of CV b15% and accuracy of b21% error were within the
acceptable limits in both assays (Tables 3 and 4).
3.2.3. Linearity of dilution
To ensure accurate quantitative assessment, the positive
samples of the assay must dilute linearly and in parallel with
the standard curve. To determine this linearity of dilution,
human serum samples containing a high‐titer of ATI or a high
concentration of IFX were used. The samples were diluted
serially 2-fold and tested using the ATI-HMSA and the IFX-
HMSA, respectively. The observed values of ATI or IFX were
plotted with the expected levels of ATI or IFX in the serum. As
shown in Fig. 4, both the R2 values and the slopes of each
linear regression curve for both assays show linearity.
3.2.4. Effects of potential interfering substances
We studied the effects of potential substance interference
in both assays by spiking in common endogenous compo-
nents of human serum and drugs methotrexate (MTX) and(%) Normalized ratio (mean) SD CV (%) n
.597 0.985 0.009 0.876 38
.571 0.979 0.010 1.026 38
.043 0.754 0.071 9.454 38
.580 0.481 0.059 12.260 38
.037 0.296 0.040 13.530 38
.759 0.179 0.028 15.698 38
.176 0.108 0.024 22.008 38
.172 0.067 0.020 30.602 38
Table 3
Assay precision of the ATI-HMSA.
Intra-assay
precision (n=3)
Inter-assay precision
Run to run (n=5) Analyst to analyst (n=3) Instrument to
instrument (n=3)
High Mid Low High Mid Low High Mid Low High Mid Low
Expected (μg/mL) 0.36 0.18 0.09 0.36 0.18 0.09 0.36 0.18 0.09 0.36 0.18 0.09
Measured (mean, μg/mL) 0.40 0.18 0.09 0.38 0.18 0.09 0.39 0.18 0.09 0.35 0.17 0.07
SD 0.01 0.01 0.00 0.03 0.01 0.00 0.02 0.01 0.01 0.02 0.01 0.01
CV (%) 1.6 3.46 1.08 6.44 6.14 3.43 4.03 5.12 6.36 4.87 3.94 11.89
Accuracy (% error) 11.85 1.78 5.5 5.18 1.02 3.39 7.04 1.35 2.63 3.63 5.06 20.78
183S-L. Wang et al. / Journal of Immunological Methods 382 (2012) 177–188Azathioprine into the three QC samples (high, mid, and low)
to determine their percent recovery. As shown in Table 5, no
significant interference was observed in the physiological
levels of serum substances and typical serum concentration
of drugs in the ATI-HMSA and IFX-HMSA as assessed by the
recovery of the mid QC samples in the presence of the
potential interfering substances because of the recovery
values were within ±10% of the mid QC control sample
except for the lipemic serum sample at a concentration of
200 mg/mL in the IFX-HMSA and the TNF-α concentration at
250 ng/mL in the ATI-HMSA. TNF-α also had some interfer-
ence in the IFX-HMSA when the concentrations were over
100 ng/mL because the recovery was greater than ±10% of
the mid QC control sample value.3.3. IFX drug tolerance of the ATI-HMSA
Substantial concentrations of IFX may be present in the
serum from patients, even if the blood is drawn at the trough
time point. As discussed previously, the presence of IFX in the
patient serum significantly affected the quantitative mea-
surement of ATI using the bridging ELISA assay. To address
this issue with the HMSA-based assays, we evaluated the
potential impact of IFX level in patient serum on ATI-HMSA
results by adding increased amounts of IFX (6.6, 20, and
60 μg/mL) to each of the eight ATI calibration standards to
assess the effects on the standard curve. As seen in Fig. 5, the
ATI-HMSA could detect ATI levels as low as 0.036 μg/mL in
the serum sample containing up to 60 μg/mL of IFX, which is
much higher than the maximum therapeutic level reached
after infusion of the patient with IFX.Table 4
Assay precision of the IFX-HMSA.
Intra-assay
precision (n=3)
Inter-assay precisi
Run to run (n=5)
High Mid Low High Mid
Expected (μg/mL) 0.63 0.31 0.16 0.63 0.31
Measured (mean, μg/mL) 0.63 0.34 0.17 0.64 0.34
SD 0.01 0.01 0.01 0.03 0.02
CV (%) 2.30 3.22 5.81 5.01 5.14
Accuracy (% error) 1.63 9.55 7.11 3.00 9.313.4. Cut point determinations for the ATI-HMSA and IFX-HMSA
To establish the cut point for the ATI-HMSA and the IFX-
HMSA, we screened 100 serum samples collected from IFX
drug-naïve healthy subjects for the measurement of ATI and
IFX levels. No shifting of the IFX-488 to the bound complex
areas was found in most of the samples of the ATI-HMSA
(Fig. 6A). The proportion of shifted area over the total area
was near the LOB and the mean value of the extrapolated ATI
from standard curve (multiplied by the dilution factor) was
0.73±0.23 μg/mL as shown in Fig. 6B. The cut point for ATI
was determined by taking the mean value +2× SD, which
yielded 1.19 μg/mL. Three samples contained ATI levels
slightly higher than the cut point, which resulted in a clinical
specificity of 97%. The same 100 serum samples were also
used to establish the cut point for the IFX-HMSA (data not
shown). The calculated cut point for IFX-HMSA was 0.98 μg/
mL, yielding a clinical specificity of 95%.
3.5. Clinical validation of the ATI-HMSA
Currently one of the clinically validated methods for
measuring ATI is by using bridging ELISA methodology (Baert
et al., 2003), which over the last decade has been used to
measure ATI in serum samples from IBD patients treated with
IFX. To evaluate the performance of the HMSA to detect ATI in
the presence of IFX compared to that of the bridging ELISA assay,
we performed ATI-HMSA on 100 serum samples obtained from
IBD patients that were previously tested to be positive for ATI by
the bridging ELISA method. The proportion of shifted area
over the total area and the interpolated ATI from the
standard curve (multiplied by the dilution factor of 50)on
Analyst to analyst (n=3) Instrument to instrument
(n=3)
Low High Mid Low High Mid Low
0.16 0.63 0.31 0.16 0.63 0.31 0.16
0.18 0.62 0.33 0.16 0.64 0.34 0.19
0.01 0.06 0.03 0.02 0.03 0.02 0.02
8.11 9.41 8.42 13.73 4.85 7.22 11.95
15.40 1.19 5.06 5.05 2.74 7.62 20.03
R2=0.9946 
P value < 0.0001 
R2=0.9940 
P value < 0.0001 
A
B
Fig. 4. Linearity of dilution for the (A) ATI-HMSA and (B) IFX-HMSA. Linearity
of the ATI-HMSA and the IFX-HMSAwere determined by a 2-fold serial dilution
of a high-titer ATI-positive sample and a high concentration IFX-positive
sample, respectively. The relationships between the observed and the expected
concentrations were plotted. Panels A and B show that the R2 value and the
slope of each linear regression curve demonstrate good linearity.
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of ATI in the patient serum samples were significantly
higher than those in the drug-naïve healthy controls
(mean±SD=9.57±11.43 vs. 0.73±0.29 μg/mL, pb0.0001)
as shown in Fig. 7A. Receiver operating characteristic curve
analysis of these samples (Fig. 7B) showed that the area under
the curve was 0.986±0.007 (95% CI: 0.973–0.999, pb0.0001),Table 5
Effects of potential interfering substances in the ATI-HMSA and IFX-HMSA (All reco
Substance Typical range Range tested
IgG 7–16mg/mL 10mg/mL
IgM 0.4–2.3 mg/mL 2.0 mg/mL
IgA 0.7–4.0 mg/mL 1.5 mg/mL
Rheumatoid factor >30 IU/mL (RA patients) Up to 774 IU/mL
Hemolyzed serum b20 Hem. Index (HI) 100–300 HI
Lipemic serum b150 mg/dL triglycerides 100–200 mg/dL
MTX 1.1 mM 2.0 mM
Azathioprine 3.6 μM 10.8 μM
TNF-α 6.2–6.6 pg/mL 0.01–250 ng/mL
TNF-β 100 pg/mL 0.01–250 ng/mL
sTNFR1 1.87–1.97 ng/mL 0.1–1000 ng/mL
sTNFR2 4.49–4.66 ng/mL 0.1–1000 ng/mLthe sensitivity was 95% (95% CI: 88.72%–98.36%), and the odds
ratio was 47.50 when a 1.19 μg/mL cut point was used. Good
correlation between the ATI values obtained from the ATI-
HMSA and the bridging ELISA was also observed, with
pb0.0001 and a Spearman r-value of 0.39 (95% CI: 0.2–0.55)
as shown in Fig. 8. Upon re-testing the three samples from the
healthy controlswith the ATI concentration above the cut point
(1.196, 1.201, and 1.219 μg/mL) using ATI-HMSA, the resulting
ATI concentrations were all below the cut point. Thus we
defined these results as false-positive. However, among the
100 ATI-positive IBD patient serum samples previously
determined by the bridging ELISA, five of the samples were
found to be ATI-negative (i.e., containing ATI concentrations
below the cut point of 1.19 μg/mL). Repeatedly re-testing these
samples showed no shift on the SE-HPLC chromatogram, thus
we defined the five samples as true negative. The increased rate
of false-positive ATI measurements with the bridging ELISA
method may be attributed to an elevated level of nonspecific
binding.
4. Discussion
Since the initial approval of the antibody drug IFX by the
United States Food and Drug Administration for the treat-
ment of Crohn's disease (CD) in 1998, the broad use of anti-
TNF therapy in IBD has dramatically improved therapeutic
outcome over the past decade (Targan et al., 1997; Colombel
et al., 2010; Present et al., 1999; Rutgeerts et al., 1999;
Hanauer et al., 2002). Nevertheless, there is a significant
number of patients that either fail to respond (primary non-
responders) or lose response (secondary non-responders) to
anti-TNF treatments. There are many factors that may
contribute to the loss of response to IFX in IBD patients,
such as the development of a complication to the disease or
uncontrolled disease activity (Miheller et al., 2012), in
addition to the formation of ATI. ATI formation negatively
affects drug efficacy by increasing the clearance of IFX and/or
neutralizing its activity, therefore reducing the amount of
active IFX in circulation (Baert et al., 2003; Hanauer et al.,
2004; Farrell et al., 2003; Miele et al., 2004). In contrast,
achieving an adequate serum IFX level is not only associated
with improved treatment response but also appears to have a
lower rate of ATI formation (Maser et al., 2006; Farrell et al.,
2003). Thus there is an interdependent relationship between
IFX levels and ATI, which underscores the importance ofvery values shown are from the mid QC controls of each assay).
ATI-HMSA IFX-HMSA
100.58±3.51% 107.89±0.65%
100.04±0.93% 104.09±0.32%
99.92±3.34% 105.43±2.09%
96.22±0.17% (774 IU/mL) 90.57±0.62% (774 IU/mL)
105.13±3.66% (300 HI) 95.76±0.78% (300 HI)
96.91±2.49% (200 mg/mL) 113.70±0.61% (200 mg/mL)
99.59±0.18% 100.90±2.71%
96.27±1.30% 100.49±2.12%
110.46±1.26% (250 ng/mL) 91.27±0.90% (100 ng/mL)
94.58±1.51% (250 ng/mL) 98.08±0.25% (100 ng/mL)
99.76±0.61% (1000 ng/ml) 94.32±2.21% (1000 ng/mL)
96.34±0.88% (1000 ng/mL) 99.20±1.13% (1000 ng/mL)
Fig. 5. ATI-HMSA drug tolerance. Interference by IFX in the ATI-HMSA was
assessed by adding increasing doses of IFX (6.6, 20, and 60 μg/mL) in each of the
eight ATI calibration standards to determine their effects on the generation of
the standard curve. The results showed that the ATI-HMSA could detect an ATI
level as low as 0.036 μg/mL in the presence of 60 μg/mL of IFX.
185S-L. Wang et al. / Journal of Immunological Methods 382 (2012) 177–188measuring andmonitoring both IFX and ATI levels accurately.
An evolving concept in the management of IBD patients with
biologic therapy involves dose optimization using an indi-
vidualized dosing regimen versus a standard “one-dose-fits-
all” regimen to attain a personalized target therapeutic drug
level (Ordas et al., 2012). This concept was demonstrated in aFig. 6. Clinical sample test and assay cut point determination for the ATI-HMSA. Seru
ATI-HMSA (cut point value was calculated as the mean value plus 2.0×SD). Panel A
area/total area obtained from the analysis. Panel B shows the interpolated ATI value
with IBD on the proportion of shifted area/total area obtained from the analysis. Paclinical study that correlated patient trough serum IFX
concentration with response and remission (Maser et al.,
2006). Recently, these findings were supported by a study of
115 UC patients where it was found that a detectable trough
serum IFX level predicted clinical remission, endoscopic
improvement, and a lower risk for colectomy, whereas, an
undetectable trough serum IFX level was associated with less
favorable outcomes (Seow et al., 2010). This proposed
treatment strategy is in contrast to the most commonly
used strategies of empirically increasing the dose, shortening
the infusion frequency, or switching to another anti-TNF
agent such as adalimumab or certolizumab pegol. A growing
body of evidence suggests that serial monitoring of serum
drug and ADA levels are important in the management and
optimization of these therapies and thus may increase the
overall response, the duration of response, and minimize
adverse effects (Ordas et al., 2012).
Many clinicians have advocated the concurrent measure-
ment of serum ATI and IFX levels in patients treated with IFX or
other anti-TNF drugs and, indeed, monitoring of various anti-
TNF drugs and their respective antibodies in IBD and RA patients
has been studied in several clinical trials using a variety of
methods (Miheller et al., 2012; Guerra et al., 2011). Different
assay techniques were used to measure the ATI and IFX
concentrations in the different trials, which may contribute to
the inconsistent results obtained between studies. Many ELISA
methods with different formats are available for commercialm samples from healthy donors and patients with IBD were analyzed by the
shows individual data from 100 healthy samples on the proportion of shifted
s. Panel C shows the individual data from 100 serum samples from patients
nel D shows the interpolated ATI values.
Fig. 7. (A) ATI concentrations in healthy control and IBD patient serum samples determined by the ATI-HMSA. The horizontal dotted line represents the cut point
and the horizontal solid line represents the mean, the y-axis scale is Log 2. (B) Plot of the receiver operating characteristic (ROC) curve using data obtained from
the ATI-HMSA analysis of healthy control and IBD patient serum samples.
186 S-L. Wang et al. / Journal of Immunological Methods 382 (2012) 177–188use, but the reliability of these methods may be questionable
because there is no standard available for comparison. Themost
commonmethod for measuring serum ATI is the bridging ELISA
as described by Baert et al. (2003). However other ELISA
methods have also been described to detect IFX and ATI in
serum samples from IBD and RA patients (Bendtzen et al., 2006,
2009; Ben-Horin et al., 2012; Imaeda et al., 2012). Some of these
assays appear to be capable of detecting ATI in the presence of
low concentrations of IFX, but the ATI-positive rates determined
by these methods varied significantly (Kopylov et al., 2011;
Imaeda et al., 2012). RIA has also been developed to measure
serum ATI and IFX concentrations, and their clinical utility was
compared to solid-phase ELISA methods (Wolbink et al., 2006;
Bendtzen et al., 2006; Svenson et al., 2007). In general, RIA has
some advantages over ELISA with fewer artifacts. However, RIA
methodology is more complex compared to ELISAmethodology
and the use of radioactive materials is a major issue in many
clinical labs. Nevertheless, despite the different ATI and IFX
results obtained using the various methods, the clinical out-
comes from most of the studies were similar, namely: 1)
Detectable levels of ATI or high-titer ATI were correlated with
low concentrations or undetectable trough levels of IFX,
respectively, and 2) patients who were ATI-positive andFig. 8. Correlation of the ATI-HMSA and bridging ELISA on the measurement
of ATI in IBD patient serum samples.possessed low trough levels of IFX had a higher rate of loss of
response to IFX treatment.
By taking advantage of homogenous fluid-phase method-
ology and avoiding the multiple washing steps of the ELISA
format, we have developed an HMSA method with the ability
to quantitativelymeasure IFX drug and ATI levels in IBD patient
serum samples. This method was based on the incubation of
IBD patient serum samples with fluorescent-labeled IFX to
detect ATI levels or with fluorescent-labeled TNF-α to detect
IFX levels. The immune complexes formed in the incubation
mixturewere separated from the free label by SE-HPLC and the
amount of ATI or IFX in the samples was calculated from the
resolved peak areas. A similar but more cumbersome method
had been applied to measure the formation, distribution, and
elimination of IFX and anti-IFX immune complexes in cyno-
molgus monkeys by using a radio-labeled monkey anti-IFX IgG
to monitor the shifting of the immune complexes in the SE-
HPLC (Rojas et al., 2005). The HMSA method overcomes many
potential artifacts encountered in the solid-phase ELISA
method because the antibody and antigen binding reactions
takes place in a homogeneous liquid-phase condition. Also, the
solid-phase ELISA method may only be able to detect high
affinity antibodies because it involves many steps of washing
and incubation that may potentially remove the antibodies
bound with low affinity. Further advantages of the HMSA
method include the potential detection of all immunoglobulin
isotypes and all subclasses of IgG, including IgG4. Analytical
validation of the ATI- and IFX-HMSA showed that the assay
performance was robust and not affected by potential inter-
fering substances present in serum. Incorporation of an acid
dissociation step during ATI-HMSA dramatically improved the
drug tolerance of the assay and allowed for an accurate
detection of ATI in the presence of high levels of IFX (up to
60 μg/mL) in serum. The use of fluorescent labeling and
fluorescent monitoring of the SE-HPLC peaks significantly
increased the analytical sensitivity for measuring ATI, which
can reach a concentration of 0.011 μg/mL, compared with the
suboptimal concentration of 200–500 ng/mL achieved by
bridging ELISA. Re-analysis of clinical samples which had
previously tested positive using a bridging ELISA method
showed that 5% of them were negative using ATI-HMSA;
otherwise, there was good correlation between the two
187S-L. Wang et al. / Journal of Immunological Methods 382 (2012) 177–188assays on the ATI-positive samples. The false‐positive rate
with the cut point of 1.19 μg/mL was 3%. However, this rate
could be reduced by repeating the test if the result is within
10% of the cut point (i.e., 1.19–1.21 μg/mL). Additional
patient samples are needed to verify the clinical utility of the
ATI- and IFX-HMSA. Because a variety of anti-TNF drugs have
been shown to induce antibody formation in clinical studies
(Bartelds et al., 2011; Karmiris et al., 2009; Lichtenstein et
al., 2010), the HMSA method may be applied to measure
other antibody drug levels and anti-drug antibodies in
patient serum samples.
In conclusion, the liquid-phase HMSA methodology
presented in this paper for the purpose of measuring ATI
and IFX in IBD patient serum samples overcomes many
limitations encountered in the solid-phase ELISA and RIA
methods. Validation of the ATI- and IFX-HMSA also showed
higher sensitivity and drug tolerance compared to that
achieved by the ELISA method. This liquid-phase HMSA
format is a useful platform that can be broadly applied to
detect anti-drug antibodies and drug levels for a variety of
protein therapeutics during drug development and post-
approval monitoring.
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